TIGIT
TIGIT is an immune brake that looked promising, then failed in several big lung cancer trials. It is a cautionary tale. This dossier gathers the 1 product (0 approved), 0 trials, 1 pathway and 1 resistance route in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Binds PVR (CD155) on tumour cells; competes with the activating receptor CD226.
- T and NK cells
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | n/a | Immune-cell target; PD-L1 used for selection | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Withdrawn or failed |
|---|---|
| Antibody 1 |
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes that involve this target
Unaddressed routes →Exhausted T cells co-express other inhibitory receptors.
- Relatlimab + nivolumab (LAG-3) works; TIGIT combinations failed
Pathways where it is a node
Pathway-to-drug matrix →- NK-cell recognition: missing self & stress ligandsNode: TIGIT vs DNAM-1 (CD155) · 2 druggable nodes
Natural killer cells patrol for cells that have lost their identity papers (MHC-I) or that display stress flags. Cancers that hide from T cells by dropping MHC-I become visible to NK cells, unless they also shed the stress flags, wrap themselves in a second inhibitory badge (HLA-E), or soak the neighbourhood in TGF-β.
Which nodes have drugs →
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →Query for this target: (TITLE:"TIGIT" OR ABSTRACT:"TIGIT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIGIT, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tigit.json. Licence CC BY 4.0.